RT Journal Article SR Electronic T1 Staging of Regional Lymph Nodes in Melanoma Patients by Means of 99mTc-MIBI Scintigraphy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1561 OP 1565 VO 44 IS 10 A1 Omar Alonso A1 Miguel Martínez A1 Lucía Delgado A1 Ana De León A1 Daniela De Boni A1 Graciela Lago A1 Mariela Garcés A1 Flávia Fontes A1 José Espasandín A1 Julio Priario YR 2003 UL http://jnm.snmjournals.org/content/44/10/1561.abstract AB Most first relapses in patients with melanoma occur in regional lymph node basins. Such lesions are frequently diagnosed clinically during the first 2 y of follow-up. In the last few years, our group has been studying the usefulness of 99mTc-methoxyisobutylisonitrile (MIBI) scintigraphy in the evaluation of recurrent melanoma lesions. The aim of the present study was to prospectively evaluate the clinical value of 99mTc-MIBI scintigraphy in the diagnosis of subclinical nodal metastases. Methods: We included 66 patients within 3 mo of melanoma diagnosis, with Breslow thickness > 1.0 mm, all treated with wide local excision of the primary lesion. When 99mTc-MIBI scanning was performed, 49 of them did not have evidence of nodal disease, and 17 had clinically questionable regional lymph node lesions. Planar images of lymph node regions were acquired 10 min after injection, using a dose of 740–1,110 MBq and a large-field-of-view gamma camera equipped with a low-energy high-resolution collimator. Scan findings were confirmed by pathology or by clinical follow-up (median, 35 mo). Results: Thirty of 33 patients with regional lymph node metastases received a correct diagnosis, 14 with palpable lesions and 16 with nonpalpable lesions. In 3 cases that were initially 99mTc-MIBI negative, nodal metastases were found during follow-up. The following diagnostic values were calculated: sensitivity, 0.91 (95% confidence interval [CI], 0.75–0.98); specificity, 0.85 (95% CI, 0.67–0.94); likelihood ratio of a positive test, 6.0 (95% CI, 2.7–13.5); and likelihood ratio of a negative test, 0.11 (95% CI, 0.036–0.32). Conclusion: 99mTc-MIBI scanning may have a secondary role in the staging of regional lymph nodes in patients with clinically localized melanoma who are not good candidates for sentinel node biopsy.